The overarching goal of the HCCC Experimental Therapeutics (ET) program is to develop and test novel cancer therapeutics. To accomplish this, ET has three central research themes: 1) Therapeutic Targets and Lead Discovery, 2) Novel Drug Delivery Approaches and 3) Clinical Therapeutics. ET has 30 full members and 17 associate members. Members have appointments across 3 colleges (Medicine, Pharmacy and Liberal Arts and Sciences) and 11 departments. Many ET members contribute to more than one theme. Total peer- reviewed annual research funding to ET is $4.33 million ($2.44 from the NCI) with $10.44 million in funding for non-peer reviewed research projects. ET members are highly productive and collaborative. ET members have authored or co-authored 305 cancer-related publications since April 1, 2011 with 49% (n=148) addressing therapeutic targets and lead discovery, 14% (n=43) addressing novel drug delivery approaches and 36% (n=108) addressing clinical therapeutics. 19% (n=59) were intra-programmatic, 37% (n=113) inter- programmatic, and 30% (n=93) inter-institutional. 26 manuscripts were published in high impact journals (impact factor >10). In the Therapeutic Targets and Lead Discovery theme, groups of investigators collaborate based on experimental therapeutics geared towards specific pathways, as well as cancer types. In the Novel Drug Delivery Approaches theme, ET investigators are evaluating nanoparticles, aptamers and novel approaches to cancer immunotherapy for treating prostate cancer, lymphoma, melanoma and breast cancer. Investigators in the Clinical Therapeutics theme are exploring mechanisms of action of clinical therapeutics and participating in or leading 145 active clinical trials across a spectrum of cancer types as coordinated through the disease specific Multidisciplinary Oncology Groups (MOGs). As a program, an increasing focus of ET is to facilitate movement of promising molecularly-targeted therapeutic approaches through the developmental therapeutics pipeline.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-18
Application #
9460397
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-04-01
Budget End
2019-03-31
Support Year
18
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Marsden, Autumn N; Derry, Sarah W; Schneider, Igor et al. (2018) The Nkd EF-hand domain modulates divergent wnt signaling outputs in zebrafish. Dev Biol 434:63-73
Rafiullah; Ali, Asad; Mohiuddin, Hafsa et al. (2018) Innovations in the Management of Hepatocellular Carcinoma. Am J Ther 25:e362-e368
Guy, Christopher L; Weiss, Elisabeth; Jan, Nuzhat et al. (2018) Technical Note: A method for quality assurance of landmark sets for use in evaluation of deformable image registration accuracy of lung parenchyma. Med Phys :
Vander Weg, Mark W; Coday, Mace; Stockton, Michelle B et al. (2018) Community-based physical activity as adjunctive smoking cessation treatment: Rationale, design, and baseline data for the Lifestyle Enhancement Program (LEAP) randomized controlled trial. Contemp Clin Trials Commun 9:50-59
Paul, Sanjoy; McDonald, W Hayes; Moye-Rowley, W Scott (2018) Negative regulation of Candida glabrata Pdr1 by the deubiquitinase subunit Bre5 occurs in a ubiquitin independent manner. Mol Microbiol 110:309-323
Swami, Umang; Zakharia, Yousef; Zhang, Jun (2018) Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother 41:359-360
Khakhina, Svetlana; Simonicova, Lucia; Moye-Rowley, W Scott (2018) Positive autoregulation and repression of transactivation are key regulatory features of the Candida glabrata Pdr1 transcription factor. Mol Microbiol 107:747-764
Weeks, Kristin S; Kahl, Amanda R; Lynch, Charles F et al. (2018) Racial/ethnic differences in thyroid cancer incidence in the United States, 2007-2014. Cancer 124:1483-1491
Curry, Susan J; Krist, Alex H; Owens, Douglas K (2018) Annual Report to the Nation on the Status of Cancer, Part II: Recent changes in prostate cancer trends and disease characteristics. Cancer :
Zhang, Liyang; Martini, Gabriella D; Rube, H Tomas et al. (2018) SelexGLM differentiates androgen and glucocorticoid receptor DNA-binding preference over an extended binding site. Genome Res 28:111-121

Showing the most recent 10 out of 1080 publications